The ACME Laboratories Ltd. (DSE: ACMELAB)

Market Cap	15.62B
Revenue (ttm)	32.35B
Net Income (ttm)	2.35B
Shares Out	211.60M
EPS (ttm)	11.11
PE Ratio	6.64
Forward PE	n/a
Dividend	3.50 (4.74%)
Ex-Dividend Date	Nov 21, 2024

Volume	79,667
Average Volume	130,883
Open	n/a
Previous Close	73.80
Day's Range	73.40 - 73.90
52-Week Range	62.60 - 94.50
Beta	0.14
RSI	47.57
Earnings Date	Jan 27, 2025

About The ACME Laboratories

The ACME Laboratories Ltd., a pharmaceutical company, engages in the manufacture, market, and distribution of generic pharmaceutical formulation products in Bangladesh. The company offers pharmaceutical products in various therapeutic areas, such as allergic disorders, analgesic, antifribinolytic, anti-infective, antiviral, artificial sweeteners, cardiovascular, central nervous system (CNS), cough and cold, diabetes, eye care and preparations, gastroprokinetic, hepatobiliary, gastrointestinal, gynaecological, hand sanitizers, hormones and stero...

• Industry: Pharmaceutical Preparations
• Founded: 1954
• Employees: 9,301
• Stock Exchange: Dhaka Stock Exchange
• Ticker Symbol: ACMELAB

Financial Performance

In 2024, The ACME Laboratories's revenue was 31.93 billion, an increase of 18.49% compared to the previous year's 26.95 billion. Earnings were 2.46 billion, an increase of 6.62%.